Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer
This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of cetuximab in combination with carboplatin and vinorelbine as second line treatment in patients with recurrent or metastatic head and neck cancer who have progressed during or after treatment with first line cisplatinum.
Head and Neck Neoplasms
DRUG: Cetuximab|DRUG: Carboplatin|DRUG: Vinorelbine
Progression-free survival, 2.5 years|Response rate, 3 years
Toxicity, 2.5 years|Median survival, 3 years|Correlation between response and evolvement in tumor biology markers., 3 years
This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of cetuximab in combination with carboplatin and vinorelbine as second line treatment in patients with recurrent or metastatic head and neck cancer who have progressed during or after treatment with first line cisplatinum.